We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → argenx SE
Save to list
Remove

argenx SE

Netherlands, Noord-holland, Amsterdam
Report a bug?
Claim ownership and edit
Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Industries
SIC
Address:

Laarderhoogtweg 25 1101 EB

Amsterdam

Noord-Holland Netherlands

Website:
Revenue
Recent news:

RTW Investments Boosts Cogent Biosciences Stake in Q1 2026

RTW Investments significantly increased its position in biotech firm Cogent Biosciences in early 2026, signaling strong conviction ahead of potential regulatory milestones for its lead drug candidate.

Source: IndexBox Mar 22, 2026

RTW Investments Acquires $210M Stake in iRhythm Holdings in Q4 2025

Analysis of RTW Investments' significant $210 million stake acquisition in digital cardiac monitoring company iRhythm Holdings during the fourth quarter of 2025.

Source: IndexBox Mar 20, 2026

Argenx Data At AAN Puts VYVGART Neuromuscular Upside In Focus

argenx (ENXTBR:ARGX) plans to present new Phase 3 data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting. The data include results in ocular myasthenia gravis, seronegative generalized myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Real world evidence and biomarker findings are also set to be shared, highlighting clinical experience with VYVGART. For investors tracking neurology focused drug developers, argenx is drawing...

Source: Simply Wall St. Mar 19, 2026

Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r

Source: MarketBeat Mar 18, 2026

Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)

Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating. The company reported earnings per share of $8.02, exceeding the projected $5.95.

Source: Insider Monkey Mar 17, 2026

Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’

Investing.com -- Deutsche Bank upgraded Argenx (EBR:ARGX) to Buy from Hold and raised its price target to €725, citing a more attractive valuation and continued commercial momentum for its key product Vyvgart despite a mixed fourth-quarter update.

Source: Investing.com Mar 11, 2026

NASDAQ - Delayed Quote - USD
ARGX
663.93 -20.57 (-3.01%)
At close March 20 20:00 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/21/2026
Market Cap: 41.89 B
Enterprise Value: 37.50 B
Trailing P/E: 33.92
Forward P/E: 25.13
PEG Ratio (5yr expected): 0.82
Price/Sales (ttm): 10.56
Price/Book (mrq): 5.61
Enterprise Value/Revenue: 9.03
Enterprise Value/EBITDA: 28.61
Financial Highlights
Profitability and Income Statement
Profit Margin: 30.50%
Return on Assets (ttm): 8.86%
Return on Equity (ttm): 20.15%
Revenue (ttm): 4.24 B
Net Income Avi to Common (ttm): 1.29 B
Diluted EPS (ttm): 19.58
Balance Sheet and Cash Flow
Total Cash (mrq): 4.44 B
Total Debt/Equity (mrq): 0.64%
Levered Free Cash Flow (ttm): 512.83 M
Company is likely to buy
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.